Evidence map›Paper›PMID 36094106›Full record

ArticleHuman gene therapy2022

Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1.

Richard H Smith, Hanan Bloomer, Danielle Fink, Keyvan Keyvanfar, Md Nasimuzzaman, Fátima Sancheznieto, Roop Dutta, Kacey Guenther Bui, Luigi J Alvarado, Thomas R Bauer and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Richard H SmithCellular and Molecular Therapeutics Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-6581-9653
Hanan BloomerCellular and Molecular Therapeutics Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Danielle FinkNeutrophil Monitoring Lab, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Keyvan KeyvanfarCellular and Molecular Therapeutics Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Md NasimuzzamanDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Fátima SancheznietoCellular and Molecular Therapeutics Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Roop DuttaCellular and Molecular Therapeutics Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kacey Guenther BuiCellular and Molecular Therapeutics Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Luigi J AlvaradoCellular and Molecular Therapeutics Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Thomas R BauerImmune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Dennis D HicksteinImmune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
David W RussellDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Punam MalikDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Johannes C M van der LooDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Steven L HighfillCenter for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Douglas B KuhnsNeutrophil Monitoring Lab, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Mehdi PiroozniaLaboratory of Bioinformatics and Computational Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Andre LarochelleCellular and Molecular Therapeutics Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-0685-2186
National Heart Lung and Blood Institute · USCincinnati Children's Hospital Medical Center · USLeidos (United States) · USNational Institutes of Health · USNational Institutes of Health Clinical Center · USUniversity of Washington · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Regenerative Therapies for Inherited Blood Disorders-Gene therapyZIAHL006172 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LAROCHELLE, ANDRE · 2013 to 2025
$13.0M
Intramural NIH HHS ZIA HL006172NCI NIH HHS 75N91019D00024NHLBI NIH HHS Z99 HL999999
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukocyte-Adhesion Deficiency SyndromeSpumavirusAnimalsAntigens, CD34CD18 AntigensGenetic VectorsHematopoietic Stem CellsHumansMiceAntigens, CD34CD18 Antigensfoamy virushematopoietic stem and progenitor cellsleukocyte adhesion deficiency type 1β2 integrin

Identifiers

PMID36094106
PMCPMC9808799
OpenAlexW4295290068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.